



Frimley Health referral criteria and patient pathway for liraglutide 3.0mg (Saxenda®) treatment

Authors: Dr Isuri Kurera (FHFT Obesity lead physician), Sala Corcoran (FHFT lead endocrine pharmacist)

Referral criteria: NICE


Body mass index (BMI) of at least 35 kg/m² (or at least 32.5 kg/m² for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population)


and

Non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre)

and

High risk of cardiovascular disease and have conditions that would be improved by weight loss such as hypertension, obstructive sleep apnoea, hyperlipidaemia.





Method of administration

Saxenda is for subcutaneous administration only. It should be injected into the abdomen, thigh or upper arm.

It should be administered once daily at any time, independent of meals. It is preferable that Saxenda is injected around the same time of the day, when the most convenient time of the day has been chosen.

Patients will be referred to the Oviva outpatient support programme where they will receive a one-off education session on the drug and administration.

Supply

Novo Nordisk has a commercial agreement, making the Saxenda brand of liraglutide available to the NHS with a discount only if it purchased through a secondary-care tier 3 weight management service.

This means, prescriptions and supply must go through the relevant hospital pharmacy.

1 pen lasts 6 days (at the 3.0mg / day dose) and 5 pens lasts 30 days.

During the initial consultation, the patient will be provided with the information pack and travel wallet by the clinician.

Sharps bins and needles will be provided by the hospital pharmacy during each patient visit.

References

- Eligibility and treatment criteria: Adult patients who meet all criteria defined in NICE TA664 <https://www.nice.org.uk/guidance/ta664/chapter/1-Recommendations>
- Dosing and drug information: Saxenda 6 mg/mL solution for injection in pre-filled pen; Summary of Product Characteristics; <https://www.medicines.org.uk/emc/product/2313>

This pathway is based on Surrey Heartlands Referral Criteria and Patient Pathway for Liraglutide 3.0mg (Saxenda®) treatment